IMHO a big catalyst will be results of preclinical trials into other neurodegenerative indications.
At the moment we have all our eggs in the ALS basket which carries a fair amount of risk. If it looks like we can bring a second indication into play then that both increases our addressable market and also spreads the risk.
I'd imagine that strong preclinical results in a second indication could easily result in a doubling of the current share price.
- Forums
- ASX - By Stock
- PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial
IMHO a big catalyst will be results of preclinical trials into...
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAA (ASX) to my watchlist
(20min delay)
|
|||||
Last
20.0¢ |
Change
0.010(5.26%) |
Mkt cap ! $92.46M |
Open | High | Low | Value | Volume |
20.0¢ | 20.0¢ | 20.0¢ | $7K | 35K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 19.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.0¢ | 249999 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 20000 | 0.195 |
5 | 382289 | 0.190 |
11 | 198716 | 0.185 |
10 | 633052 | 0.180 |
10 | 482365 | 0.175 |
Price($) | Vol. | No. |
---|---|---|
0.200 | 249999 | 2 |
0.205 | 92540 | 5 |
0.210 | 312745 | 8 |
0.215 | 273820 | 8 |
0.220 | 669543 | 9 |
Last trade - 10.06am 03/10/2024 (20 minute delay) ? |
Featured News
PAA (ASX) Chart |